the package insert of the medicine Clenil.
Prevention and treatment of bronchial asthma and other conditions of broncoestenose, as well as perennial allergic rhinitis or seasonal, rhinitis vasomotor, the rinofaringites, sinusitis and other inflammatory affections, and allergic nasal cavities and paranasal sinuses or pharynx. Is indicated in the prevention of recurrence of nasal polyps after surgical removal.
When should I not use?
known Hypersensitivity to the components of the formula. The presence of infections, viral, fungal, or tuberculosis of the lung.
How to use?
aerosol therapy: place the stated volume on the unit. Adults: 1 flaconete 2 ml for each administration, 1 or 2 times a day. Children: half of a flaconete 1 ml for each administration, 1 or 2 times a day. (1 ml corresponds to 30 drops). Shake the flaconetes before use. – Overdosage: the administration of high doses of dipropionate of beclometasone in a short time interval can lead to the temporarily blanking function hypothalamic-pituitary-adrenal axis. In this case, the dosage should be immediately reduced to the recommended levels and the patient observed carefully. Elderly patients: the doses prescribed for adults, are very well tolerated by elderly patients, there is no need for reduction posológica.
What are the evils that can cause me?
The systemic effects are extremely unlikely because of the low doses recommended. Care should be taken during prolonged use, monitoring the patient to detect as early as possible systemic side effects such as osteoporosis, peptic ulcer disease, or signs of adrenal insufficiency secondary. In some patients undergoing aerosol therapy may occur candidiasis of the mouth and pharynx. The incidence of candidiasis appears to be related to the dose administered. This disease responds to treatment and can be prevented by washing the oral cavity with water. Can occur, in the same way as with any other topical products nasal, burning in the local, irritation, dryness of the nasal mucosa, and rarely epistaxis.
Warnings and Precautions
what should I know before using?
Use the product only in the acute stages or the initial of the disease and to avoid treatments in the long term. The prolonged use of topical medicines can cause phenomena of sensitization and, in exceptional cases, systemic side effects typical of this therapeutic class. In this case the treatment should be stopped and an appropriate treatment. Any infections of the nasal cavity, and paranasal sinuses should be treated with specific therapy, and does not constitute, however, a counter-indication of specific treatment with Clenil A. Although the product control the majority of the cases of allergic rhinitis due to change of station (seasonal), a stimulus-allergen exceptionally high may require further treatment, especially for the ocular symptoms. The change of a steroid treatment in systemic Clenil must be made with caution when there is suspicion of adrenal insufficiency. In case the patient is subjected to intense stress or presents a serious asthma attack, you should be done further treatment with corticosteroid systemic. There is no account, until the time of the appearance of reducing the levels of cortisol the plasma with the treatment with Clenil A. However, such a reduction may occur in patients receiving twice the recommended maximum dose of dipropionate of beclometasone administered by aerosol is pressurized. You must maintain proper control of patients under prolonged treatment. Therapy with corticosteroids may increase the risk of development of serious infections or even fatal in individuals exposed to viral illnesses such as chickenpox. Use during pregnancy or lactation: reproduction studies in animals, the typical side effects of corticosteroids potent were observed only with administration of systemic high-dose. However, administration by inhalation or nasal, oral dipropionate de beclomethasone prevents high plasma levels are achieved as occurs with the administration of systemic. The use of Clenil during pregnancy should be considered only when the expected benefit to the mother exceeds the possible risk to the fetus. The dipropionate of beclometasone has been used widely for several years of daily clinical, no report of apparent damage. It is reasonable to assume that there will be passage of the dipropionate of beclometasone to the breast milk but is unlikely to meet the levels achieved to be significant at the doses used in the aerosol. However, the use of the dipropionate of beclometasone during lactation requires a careful assessment of risk/benefit, both for the mother and for the child.